Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide Acetate in Advanced Prostate Cancer
NCT00166725Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2004
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of octreotide in prostate cancer (PCa) (2 arms), sponsored by Novartis. Primary endpoint: Time to 25% decrease in chromogranin A plasma level. Started Feb 2004; status: completed.
02
Drugs
octreotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00166725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00166725.